Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 8:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pterygium Clear all
Completed Phase 2 Interventional Results available

RMP-A03 Ocular Suspension in Patients With Pterygium

NCT05794204
View directory record Official record
Conditions
Pterygium
Interventions
RMP-A03 - Dose 1, RMP-A03 - Dose 2, RMP-A03 Placebo
Drug
Lead sponsor
Suzhou Raymon Pharmaceuticals Company, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Glendale, California • Inglewood, California • Newport Beach, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 9, 2026, 8:59 AM EDT
Completed No phase listed Observational

Phenotype and Etiology of Pallister-Hall Syndrome

NCT00001404
View directory record Official record
Conditions
Malformations, Multiple Abnormalies, Polydactyly
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
1,170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Bethesda, Maryland • Greenwood, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 1 Interventional

Ranibizumab for the Inhibition of Neovascularization in Pterygia

NCT00768963
View directory record Official record
Conditions
Pterygium
Interventions
ranibizumab
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2017 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease

NCT00685373
View directory record Official record
Conditions
Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome, Neonatal Onset Multisystem Inflammatory Disease
Interventions
Canakinumab (ACZ885)
Drug
Lead sponsor
Novartis
Industry
Eligibility
3 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Little Rock, Arkansas • San Francisco, California • Columbus, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome

NCT00465985
View directory record Official record
Conditions
Muckle Wells Syndrome
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
4 Years to 75 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
3
States / cities
San Francisco, California • Chicago, Illinois • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 27, 2017 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 4 Interventional

Dextenza in Pterygium Surgery

NCT04403516
View directory record Official record
Conditions
Pterygium
Interventions
Dexamethasone Intracanalicular Insert, 0.4mg, Prednisolone Acetate 1%
Drug
Lead sponsor
Michelle Rhee MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

The Effect of Bevacizumab (Avastin) on Pterygium

NCT00592176
View directory record Official record
Conditions
Pterygium
Interventions
local injection of bevacizumab
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza for Post-operative Treatment of Pterygium

NCT04351737
View directory record Official record
Conditions
Pterygium of Both Eyes
Interventions
Intracanalicular Dexamethasone, (0.4 mg) Insert, Prednisolone Acetate
Drug
Lead sponsor
Brandon Eye Associates, PA
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brandon, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety Study of Avastin Used as Adjunctive Therapy in Pterygium Surgery

NCT01115517
View directory record Official record
Conditions
Pterygium
Interventions
Bevacizumab, Mitomycin C
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 20, 2016 · Synced Sep 9, 2026, 8:59 AM EDT
Completed No phase listed Observational

Research Study on Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy (CADASIL)

NCT01114815
View directory record Official record
Conditions
CADASIL
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2013 · Synced Sep 9, 2026, 8:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene

NCT04123626
View directory record Official record
Conditions
Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders
Interventions
QR-1123, Sham procedure
Drug · Other
Lead sponsor
ProQR Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
5
States / cities
Aurora, Colorado • Gainesville, Florida • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Efficacy and Safety of Sub-tenon Ranibizumab for Recurrent Pterygia

NCT01169909
View directory record Official record
Conditions
Pterygium
Interventions
Ranibizumab
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of CBT-001 Ophthalmic Solution in Patients With Pterygium

NCT03049852
View directory record Official record
Conditions
Pterygium
Interventions
CBT-001 single dose, Vehicle, CBT-001 Multi-dose
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Laguna Beach, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2020 · Synced Sep 9, 2026, 8:59 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium

NCT05456425
View directory record Official record
Conditions
Pterygium
Interventions
CBT-001, Vehicle
Drug
Lead sponsor
Cloudbreak Therapeutics, LLC
Industry
Eligibility
12 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Dothan, Alabama • Sun City, Arizona • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2025 · Synced Sep 9, 2026, 8:59 AM EDT
Recruiting No phase listed Observational

HoFH, the International Clinical Collaborators Registry

NCT04815005
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
Demographics, diagnosis type, genotype, lipid profile, treatment allocation, country of residence.
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Sep 9, 2026, 8:59 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cyclosporine Ophthalmic Emulsion in Patients With Primary Pterygium

NCT01109056
View directory record Official record
Conditions
Pterygium
Interventions
cyclosporine ophthalmic emulsion 0.05%, Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2012 · Synced Sep 9, 2026, 8:59 AM EDT